05/05/2026 J&J announced Phase 2b data from two studies in IBD J&J announced Phase 3 results for guselkumab in CD Avalo Therapeutics announced positive Phase 2 results for abdakibart in HS J&J announced Phase 2b data from two studies in IBD (Ref) Johnson & Johnson announced data from two Phase 2b studies, DUET-UC/ NCT05242484 and DUET-CD/ NCT05242471, which evaluated JNJ-4804 (IL-23 and TNF-α) in patients with moderately to severely active ulcerative colitis (UC) and Crohn’s

21/02/2026 Three-year data demonstrated sustained clinical and endoscopic remission in ulcerative colitis with guselkumab Three-year data demonstrated sustained clinical and endoscopic remission in ulcerative colitis with guselkumab ( Ref ) Johnson & Johnson announced new long-term data from the Phase 2b/3 QUASAR/ NCT04033445 study evaluating TREMFYA® (guselkumab; anti-IL-23) in adult patients with moderately-to-severely active ulcerative colitis (UC) In this study, guselkuma